Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Event Calendar

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Event Calendar
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement
|Articles|October 23, 2018

The Future of JAK Inhibitors Figure 1

Author(s)Denise Baldock, Elizabeth Baynton, Amanda Baskett, and Nicola Bailey
Advertisement
External Link - Future-of-JAKs_Figure 1.pdf

Advertisement
R&D/Clinical Trials

Related Content

Advertisement
stock.adobe.com

CSPC Pharmaceutical & AstraZeneca Form Joint Venture for Biologics Manufacturing in China

ByNicholas Jacobus
August 5th 2026
For complex biologics, such as multispecific antibodies or antibody drug conjugates, the modality itself is a coordination puzzle. Credit: Stock.Adobe.com/anamejia18.

Why Biologics R&D Platforms Are Failing Complex Modalities and What Must Change

ByChristian Olsen
August 3rd 2026

Why Real-Time Data Analytics Are Vital for the Next Evolution of Clinical Trials

ByChristian Schmidt
July 31st 2026
stock.adobe.com FDA vote

FDA CTGTAC Committee Votes in Favor of Replimune’s RP1 Efficiency Results in Ignyte Study

ByNicholas Jacobus
July 31st 2026
stock.adobe.com business deal

M&A Roundup: Johnson & Johnson Collaborates with Sail Biomedicines, Processa Pharmaceuticals Acquires Vidya Therapeutics, Relation Collaborates with GSK

ByNicholas Jacobus
July 30th 2026
Advertisement
Advertisement

Trending on PharmExec

1

Amazon Pharmacy Launches GLP-1 Delivery Service

2

Pharmaceutical Executive Daily: Amazon Pharmacy to Offer GLP-1 Delivery Service

3

FDA Approves Moderna's mRNA-Based Flu Vaccine

4

Beyond the Megamerger: How Rumored AstraZeneca–BMS Discussions Signal a New Era of Pharmaceutical Competition

5

Your Questions Answered: The Biggest Pharma Stories of the Week of August 3-7, 2026

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us